Analystreport

BioMarin Pharmaceutical (BMRN) had its price target lowered by Guggenheim from $106.00 to $86.00. They now have a "buy" rating on the stock.

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com